{"preliminary_commentary":{"by_channel":{"x_thread":10,"youtube":2,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06018337\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"DYNASTY-Breast02","nct_id":"NCT06018337","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=dynasty-breast02-nct06018337. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Enrolled Subjects will be randomized to receive a 8 mg/kg IV dose of DB-1303/BNT323 on Day 1 of each cycle Q3W","label":"DB-1303/BNT323","type":"EXPERIMENTAL"},{"description":"Enrolled Subjects will be randomized to receive investigator's choice single agent chemotherapy (capecitabine:1000 or 1250 mg/m2, Oral, Twice daily orally for 2 weeks followed by a 1-week rest period in 3-week cycles; paclitaxel：80 mg/m2， IV, Every week (QW) in 3-week cycles; or nab-paclitaxel: 100 mg/m2, IV, Every week (QW) for 3 weeks followed by a one-week rest period in 4-week cycles) until RECIST 1.1 defined disease progression (PD), unless there is unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation is met.","label":"investigator's choice single agent chemotherapy","type":"ACTIVE_COMPARATOR"}],"collaborators":["BioNTech SE"],"completion_date":{"date":"2028-08","type":"ESTIMATED"},"conditions":["Metastatic Breast Cancer"],"enrollment":{"count":541,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"DB-1303/BNT323","otherNames":[],"type":"DRUG"},{"name":"Capecitabine","otherNames":[],"type":"DRUG"},{"name":"Paclitaxel","otherNames":[],"type":"DRUG"},{"name":"Nab-paclitaxel","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-24","lead_sponsor":"DualityBio Inc.","official_title":"A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-08-12","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free survival (PFS) in the HR+, HER2-low population","timeFrame":"Up to approximately 51 months"}],"references":[],"start_date":{"date":"2024-01-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)","url":"https://clinicaltrials.gov/study/NCT06018337"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/dynasty-breast02-nct06018337"}